Form 4: KALA BIO Director Farid Marjan Reports Stock and Option Transactions

Director Farid Marjan reports acquisition of restricted stock units and stock options in KALA BIO, Inc.

Summary

• On June 11, 2024, Farid Marjan, a director of KALA BIO, Inc., reported the acquisition of 1,400 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs were granted under the Issuer's Amended and Restated 2017 Equity Incentive Plan.
• The RSUs will vest as to 100% of the shares on the earlier of June 11, 2025, or the date of the first annual meeting following June 11, 2024, subject to continued service.
• Marjan also acquired a stock option to buy 3,150 shares of common stock at an exercise price of $6.18.
• This option was granted on June 11, 2024, and vests as to 100% of the shares on the earlier of June 11, 2025, or the date of the first annual meeting following June 11, 2024.
• Following these transactions, Marjan beneficially owns 7,792 shares of common stock, including 6,692 unvested RSUs, and options to purchase 3,150 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard equity compensation practices, aligning director interests with shareholders. There are no indications of negative events or concerns.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs and stock options.

Industry Context

This filing is a routine disclosure of equity-based compensation to a company director, which is a common practice in publicly traded companies to incentivize and retain key personnel. It is typical for biotech companies to use equity compensation extensively.

Comparison to Industry Standards

• Equity compensation for directors is a standard practice across the biotechnology industry.
• Companies like Amgen, Biogen, and Gilead Sciences also grant stock options and restricted stock units to their directors as part of their compensation packages.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term value creation.

Stakeholder Impact

• The grant of equity to a director can positively impact shareholders by aligning management's interests with long-term company performance.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates